EXL01

Phase 2Small molecule

EExeliom Biosciences

EXL01 is one of 46 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Clostridioides Difficile InfectionActive, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Clostridioides Difficile InfectionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Viread

Gilead

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

EXL01

EExeliom Biosciences

Phase 2

1 6

Hepsera

Coreg

2 8

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 9

Opdivo

Bristol-Myers Squibb

Preclinical

2 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT06551272

Q1 2028

PreclinicalRecruiting

Clostridioides Difficile Infection

NCT06306014

Q4 2028

Phase 1/2Recruiting

Advanced NSCLC

NCT06448572

Q2 2029

Phase 2Recruiting

Gastric Cancer

NCT06253611

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

Recruiting·CCenter Eugene Marquis·Phase 2·NCT06551272·34 enrolled

Gastric Cancer1 trial

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT06253611·120 enrolled

Crohn's Disease1 trial

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Terminated·EExeliom Biosciences·Phase 1·NCT05542355·8 enrolled

Advanced NSCLC1 trial

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

Recruiting·UUniversity Hospital, Lille·Phase 1/2·NCT06448572·21 enrolled

Clostridioides difficile Infection1 trial

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

Recruiting·HHospices Civils de Lyon·Preclinical·NCT06306014·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for EXL01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EXL01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EXL01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Exeliom Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EExeliom Biosciences

EXL01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q4 2028

Q2 2029

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Gastric Cancer1 trial

Crohn's Disease1 trial

Advanced NSCLC1 trial

Clostridioides difficile Infection1 trial

References

Drug Info

Quick Facts

Related News